Excess mortality after craniopharyngioma treatment: are we making progress?
- PMID: 30569259
- DOI: 10.1007/s12020-018-1830-y
Excess mortality after craniopharyngioma treatment: are we making progress?
Abstract
Purpose: Craniopharyngioma is associated with an increased risk of mortality even after surgical, radiotherapeutic and hormone supplementations. Previous studies using different designs showed a possible trend of decreasing mortality in recent years. This review summarises studies reporting standardised mortality ratio (SMR) after craniopharyngioma treatment, as well as the bias and confounding in these studies to plan further researches.
Methods: PubMed and Embase was searched for manuscripts published before October 2018 using medical subject heading terms ("craniopharyngioma" or "hypopituitarism" and "mortality").
Results: Eight studies reported SMR after craniopharyngioma treatment, with a total of 2802 patients. The subgroup meta-analysis using random effects model was conducted to pool the SMR, which was 6.2 (95% CI 4.1-9.4) before 2010 and 2.9 (95% CI 2.2-3.8) after 2010 (subgroup test p < 0.01), respectively. Misclassification (one study) and selection bias (six studies) either inflated or deflated the result. The trend of increasing survival rate over the time was observed in studies without reporting SMR. Female patients, childhood-onset disease, hydrocephalus, tumour recurrence, body mass index and panhypopituitarism were identified as the important risk factors for excess mortality.
Conclusions: Though bias and confounding existed across studies, the decreasing SMR and increasing survival rate over the time was in favour of a real signal. It is necessary to launch studies to further investigate the morality and risk factors after multidisciplinary treatment of craniopharyngioma in a hospital-based manner, using the modern statistical method to adjust for bias and confounding.
Keywords: Craniopharyngioma; Hypopituitarism; Mortality; Survival.
Similar articles
-
Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study.Eur J Endocrinol. 2018 Jan;178(1):93-102. doi: 10.1530/EJE-17-0707. Epub 2017 Oct 18. Eur J Endocrinol. 2018. PMID: 29046325
-
Mortality in adults with hypopituitarism: a systematic review and meta-analysis.Endocrine. 2017 Apr;56(1):33-42. doi: 10.1007/s12020-016-1159-3. Epub 2016 Nov 5. Endocrine. 2017. PMID: 27817141 Review.
-
High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma.Clin Endocrinol (Oxf). 2005 Feb;62(2):197-204. doi: 10.1111/j.1365-2265.2004.02196.x. Clin Endocrinol (Oxf). 2005. PMID: 15670196 Review.
-
Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011.Neuro Oncol. 2013 Jun;15(6):767-74. doi: 10.1093/neuonc/not026. Epub 2013 Mar 13. Neuro Oncol. 2013. PMID: 23486689 Free PMC article. Clinical Trial.
-
Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence.J Clin Endocrinol Metab. 1998 Nov;83(11):3897-904. doi: 10.1210/jcem.83.11.5240. J Clin Endocrinol Metab. 1998. PMID: 9814465
Cited by
-
Deep-learning-based automatic segmentation and classification for craniopharyngiomas.Front Oncol. 2023 May 5;13:1048841. doi: 10.3389/fonc.2023.1048841. eCollection 2023. Front Oncol. 2023. PMID: 37213305 Free PMC article.
-
A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity.J Endocr Soc. 2023 Mar 17;7(5):bvad037. doi: 10.1210/jendso/bvad037. eCollection 2023 Mar 6. J Endocr Soc. 2023. PMID: 37153702 Free PMC article.
-
Socio-behavioral dysfunction in disorders of hypothalamic-pituitary involvement: The potential role of disease-induced oxytocin and vasopressin signaling deficits.Neurosci Biobehav Rev. 2022 Sep;140:104770. doi: 10.1016/j.neubiorev.2022.104770. Epub 2022 Jul 6. Neurosci Biobehav Rev. 2022. PMID: 35803395 Free PMC article. Review.
-
Clinical Outcomes of Transcranial and Endoscopic Endonasal Surgery for Craniopharyngiomas: A Single-Institution Experience.Front Oncol. 2022 Feb 10;12:755342. doi: 10.3389/fonc.2022.755342. eCollection 2022. Front Oncol. 2022. PMID: 35223463 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical